Lupin launches tetrabenazine tablets

Pharma major Lupin on receiving approval from the USFDA has launched Tetrabenazine Tablets. The shares of the company were trading in green.

Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg, is the generic equivalent of Valeant Pharma’s Xenazine tablets. It is indicated for the treatment of chorea associated with Huntington’s disease. Xenazine tablets had annual sales of US$153 million in the US according to IQVIA MAT September 2018 data.

Pharmaceutical company Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The company offers products in the cardiovascular, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The company is a pioneer in the anti-tuberculosis (anti-TB) treatment and cephalosporins therapy areas.

On Wednesday, the shares of the company opened at Rs. 854.40 per share against Tuesday’s close of Rs. 848.75 on the BSE. At 12:02 hours, the shares of the company were trading at Rs 850.05, up by 0.03 per cent. The intraday high was Rs 857.40 and intraday low was Rs. 846.40 per share on the BSE. Its 52-week high was Rs. 986 and 52-week low was Rs. 723.55 per share on the BSE.

Meanwhile, BSE Sensex was at 35,157.52, down by 0.89 per cent.